The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Open accessAbstract
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activators of transcription (STATs). Inhibition of JAKs can simultaneously block the function of multiple cytokines. Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatology can either be used systemically as oral drugs or locally in topical formulations. Inhibition of JAKs has been shown to be effective in various skin disorders. The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis. Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-versus-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo. Here, we aim to discuss the immunological basis and current stage of development of JAKi in dermatology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
A Road Map for Those Who Don't Know JAK-STAT
Aaronson, D. S., & Horvath, C. M. (2002) · Science · doi:10.1126/science.1071545 · Cited by 1,337
New insights into the immunopathogenesis of systemic lupus erythematosus
Tsokos, G. C., Lo, M. S., Reis, P. C., & Sullivan, K. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.186 · Cited by 1,226
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149 · cited 10×
“LOF mutations within the TYK2 gene are even rarer than JAK3 mutations (22).”
BackgroundInfluentialSelf-citationDalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 877
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Translocation of a gut pathobiont drives autoimmunity in mice and humans
Manfredo Vieira, S., Hiltensperger, M., Kumar, V., Zegarra-Ruiz, D., Dehner, C., Khan, N., Costa, F. R. C., Tiniakou, E., Greiling, T., Ruff, W., et al. (2018) · Science · doi:10.1126/science.aar7201 · Cited by 839
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W. V., et al. (2010) · Nature · doi:10.1038/nature09114 · Cited by 830
Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 803
Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B. J., & DiGiovanni, J. (2005) · Nature Medicine · doi:10.1038/nm1162 · Cited by 752
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.009 · Cited by 702
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
Self-citationDefective Lymphoid Development in Mice Lacking Jak3
Nosaka, T., van Deursen, J. M. A., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C., & Ihle, J. N. (1995) · Science · doi:10.1126/science.270.5237.800 · Cited by 637
Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis
Greenberg, S. A., Pinkus, J. L., Pinkus, G. S., Burleson, T., Sanoudou, D., Tawil, R., Barohn, R. J., Saperstein, D. S., Briemberg, H. R., Ericsson, M., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20464 · Cited by 621
Gilhar, A., Etzioni, A., & Paus, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1103442 · Cited by 609
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98814 · Cited by 536
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Wallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31363-1 · Cited by 513
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Gladman, D., Rigby, W., Azevedo, V. F., Behrens, F., Blanco, R., Kaszuba, A., Kudlacz, E., Wang, C., Menon, S., Hendrikx, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615977 · Cited by 510
Fleischmann, R., Mysler, E., Hall, S., Kivitz, A. J., Moots, R. J., Luo, Z., DeMasi, R., Soma, K., Zhang, R., Takiya, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31618-5 · Cited by 499
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
Zorn, E., Kim, H. T., Lee, S. J., Floyd, B. H., Litsa, D., Arumugarajah, S., Bellucci, R., Alyea, E. P., Antin, J. H., Soiffer, R. J., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1257 · Cited by 467
γ-Secretase Gene Mutations in Familial Acne Inversa
Wang, B., Yang, W., Wen, W., Sun, J., Su, B., Liu, B., Ma, D., Lv, D., Wen, Y., Qu, T., et al. (2010) · Science · doi:10.1126/science.1196284 · Cited by 451
Classification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice
Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00054-6 · Cited by 420
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420
Diagnosis and Treatment of Lichen Sclerosus: An Update
Fistarol, S. K., & Itin, P. H. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-012-0006-4 · Cited by 415
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-543736 · Cited by 401
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Thirunavukkarasu, K., DeMasi, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210457 · Cited by 393
Harris, J. E., Harris, T. H., Weninger, W., John Wherry, E., Hunter, C. A., & Turka, L. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.463 · Cited by 389
Lin, M.-T., Storer, B., Martin, P. J., Tseng, L.-H., Gooley, T., Chen, P.-J., & Hansen, J. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022060 · Cited by 382
Genetic susceptibility to systemic lupus erythematosus in the genomic era
Deng, Y., & Tsao, B. P. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.176 · Cited by 379
IL-33 can promote survival, adhesion and cytokine production in human mast cells
Iikura, M., Suto, H., Kajiwara, N., Oboki, K., Ohno, T., Okayama, Y., Saito, H., Galli, S. J., & Nakae, S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700663 · Cited by 370
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
Kreins, A. Y., Ciancanelli, M. J., Okada, S., Kong, X.-F., Ramírez-Alejo, N., Kilic, S. S., El Baghdadi, J., Nonoyama, S., Mahdaviani, S. A., Ailal, F., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140280 · Cited by 363
Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Le Cleach, L., & Chosidow, O. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1103641 · Cited by 356
Fox, R. I., Michelson, P., Casiano, C. A., Hayashi, J., & Stern, M. (2000) · Clinics in Dermatology · doi:10.1016/s0738-081x(00)00135-8 · Cited by 355
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Menon, M., Blair, P. A., Isenberg, D. A., & Mauri, C. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.012 · Cited by 353
Taïeb, A., & Picardo, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0804388 · Cited by 352
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.007 · Cited by 349
Simpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J., Terry, K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 320
Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317
Functional STAT3 deficiency compromises the generation of human T follicular helper cells
Ma, C. S., Avery, D. T., Chan, A., Batten, M., Bustamante, J., Boisson-Dupuis, S., Arkwright, P. D., Kreins, A. Y., Averbuch, D., Engelhard, D., et al. (2012) · Blood · doi:10.1182/blood-2011-11-392985 · Cited by 314
Choi, Y. S., Eto, D., Yang, J. A., Lao, C., & Crotty, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203032 · Cited by 307
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016) · JCI Insight · doi:10.1172/jci.insight.89790 · Cited by 297
Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., & Winthrop, K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209131 · Cited by 285
Chu, S.-Y., Chen, Y.-J., Tseng, W.-C., Lin, M.-W., Chen, T.-J., Hwang, C.-Y., Chen, C.-C., Lee, D.-D., Chang, Y.-T., Wang, W.-J., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.08.032 · Cited by 272
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Wańkowicz-Kalińska, A., van den Wijngaard, R. M. J. G. J., Tigges, B. J., Westerhof, W., Ogg, G. S., Cerundolo, V., Storkus, W. J., & Das, P. K. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069521.42488.1b · Cited by 262
Goh, C., Finkel, M., Christos, P., & Sinha, A. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01676.x · Cited by 261
Czarnowicki, T., Krueger, J. G., & Guttman-Yassky, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.004 · Cited by 260
Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Wolk, K., Warszawska, K., Hoeflich, C., Witte, E., Schneider-Burrus, S., Witte, K., Kunz, S., Buss, A., Roewert, H. J., Krause, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903907 · Cited by 254
Ruxolitinib‐associated infections: A systematic review and meta‐analysis
Lussana, F., Cattaneo, M., Rambaldi, A., & Squizzato, A. (2018) · American Journal of Hematology · doi:10.1002/ajh.24976 · Cited by 250
Winthrop, K. L., Park, S.-H., Gul, A., Cardiel, M. H., Gomez-Reino, J. J., Tanaka, Y., Kwok, K., Lukic, T., Mortensen, E., Ponce de Leon, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207319 · Cited by 249
Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Nakano, M., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.018 · Cited by 248
Sandborn, W. J., Panés, J., D’Haens, G. R., Sands, B. E., Su, C., Moscariello, M., Jones, T., Pedersen, R., Friedman, G. S., Lawendy, N., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.035 · Cited by 248
Pemphigus: Current and Future Therapeutic Strategies
Didona, D., Maglie, R., Eming, R., & Hertl, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01418 · Cited by 245
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Ghoreschi, K., Laurence, A., & O'Shea, J. J. (2009) · Nature Immunology · doi:10.1038/ni.1701 · Cited by 241
Self-citationLiu, L. Y., Strassner, J. P., Refat, M. A., Harris, J. E., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.043 · Cited by 241
Cavet, J., Dickinson, A. M., Norden, J., Taylor, P. R. A., Jackson, G. H., & Middleton, P. G. (2001) · Blood · doi:10.1182/blood.v98.5.1594 · Cited by 235
Grimes, P. E., Morris, R., Avaniss-Aghajani, E., Soriano, T., Meraz, M., & Metzger, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.031 · Cited by 231
Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., Checchio, T., Tensfeldt, T. G., Hoffman, E., Riese, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0880-2 · Cited by 223
Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 222
Mendonça, C. O., & Griffiths, C. E. M. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07155.x · Cited by 219
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1700366 · Cited by 219
History of atopy or autoimmunity increases risk of alopecia areata
Barahmani, N., Schabath, M. B., & Duvic, M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.04.031 · Cited by 218
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy, L. L., Urban, J., & King, B. A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.06.045 · Cited by 216
Molecular profiles of inflammatory myopathies
Greenberg, S. A., Sanoudou, D., Haslett, J. N., Kohane, I. S., Kunkel, L. M., Beggs, A. H., & Amato, A. A. (2002) · Neurology · doi:10.1212/wnl.59.8.1170 · Cited by 213
JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
Phan, K., & Sebaratnam, D. F. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15489 · Cited by 213
JAK Inhibitors for Atopic Dermatitis: An Update
He, H., & Guttman-Yassky, E. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0413-2 · Cited by 212
Cutaneous Graft-versus-Host Disease
Aractingi, S., & Chosidow, O. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.5.602 · Cited by 210
Clinical improvement in psoriasis with specific targeting of interleukin-23
Kopp, T., Riedl, E., Bangert, C., Bowman, E. P., Greisenegger, E., Horowitz, A., Kittler, H., Blumenschein, W. M., McClanahan, T. K., Marbury, T., et al. (2015) · Nature · doi:10.1038/nature14175 · Cited by 210
Ports, W. C., Khan, S., Lan, S., Lamba, M., Bolduc, C., Bissonnette, R., & Papp, K. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12266 · Cited by 204
The immunogenetics of Behçet's disease: A comprehensive review
Takeuchi, M., Kastner, D. L., & Remmers, E. F. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.013 · Cited by 201
T cell pathology in skin inflammation
Sabat, R., Wolk, K., Loyal, L., Döcke, W.-D., & Ghoreschi, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00742-7 · Cited by 201
Self-citationBlok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14338 · Cited by 193
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky, W., Thakral, D., Emeagwali, N., Galan, A., & King, B. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805958 · Cited by 193
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Rothstein, B., Joshipura, D., Saraiya, A., Abdat, R., Ashkar, H., Turkowski, Y., Sheth, V., Huang, V., Au, S. C., Kachuk, C., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.02.049 · Cited by 189
Jabbari, A., Sansaricq, F., Cerise, J., Chen, J. C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.032 · Cited by 188
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Punwani, N., Scherle, P., Flores, R., Shi, J., Liang, J., Yeleswaram, S., Levy, R., Williams, W., & Gottlieb, A. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.12.018 · Cited by 185
IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus
Shao, S., Tsoi, L. C., Sarkar, M. K., Xing, X., Xue, K., Uppala, R., Berthier, C. C., Zeng, C., Patrick, M., Billi, A. C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7561 · Cited by 185
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
Alves de Medeiros, A. K., Speeckaert, R., Desmet, E., Van Gele, M., De Schepper, S., & Lambert, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164080 · Cited by 184
Terlou, A., Santegoets, L. A. M., van der Meijden, W. I., Heijmans-Antonissen, C., Swagemakers, S. M. A., van der Spek, P. J., Ewing, P. C., van Beurden, M., Helmerhorst, T. J. M., & Blok, L. J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.369 · Cited by 183
Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa
Hotz, C., Boniotto, M., Guguin, A., Surenaud, M., Jean-Louis, F., Tisserand, P., Ortonne, N., Hersant, B., Bosc, R., Poli, F., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.036 · Cited by 179
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow, B. G., Liu, L. Y., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.006 · Cited by 179
Immune response patterns in non‐communicable inflammatory skin diseases
Eyerich, K., & Eyerich, S. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14673 · Cited by 179
Curtis, J. R., Lee, E. B., Kaplan, I. V., Kwok, K., Geier, J., Benda, B., Soma, K., Wang, L., & Riese, R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205847 · Cited by 170
Vazquez, M. L., Kaila, N., Strohbach, J. W., Trzupek, J. D., Brown, M. F., Flanagan, M. E., Mitton-Fry, M. J., Johnson, T. A., TenBrink, R. E., Arnold, E. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01598 · Cited by 169
Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
Welsch, K., Holstein, J., Laurence, A., & Ghoreschi, K. (2017) · European Journal of Immunology · doi:10.1002/eji.201646680 · Cited by 168
Self-citationPF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Xu, H., Jesson, M. I., Seneviratne, U. I., Lin, T. H., Sharif, M. N., Xue, L., Nguyen, C., Everley, R. A., Trujillo, J. I., Johnson, D. S., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00188 · Cited by 163
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D. G. F., Bieber, T. R. M., & Wenzel, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412997 · Cited by 156
Bissonnette, R., Iversen, L., Sofen, H. L., Griffiths, C. E. M., Foley, P. A., Romiti, R., Bachinsky, M., Rottinghaus, S. T., Tan, H., Proulx, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13551 · Cited by 151
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott, I. C., Hider, S., & Scott, D. L. (2018) · Drug Safety · doi:10.1007/s40264-018-0651-5 · Cited by 150
Alunno, A., Padjen, I., Fanouriakis, A., & Boumpas, D. T. (2019) · Cells · doi:10.3390/cells8080898 · Cited by 148
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky, W., Thakral, D., McGeary, M. K., Leventhal, J. S., Galan, A., & King, B. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.098 · Cited by 145
Krueger, J. G., Clark, J. D., Suárez‐Fariñas, M., Fuentes‐Duculan, J., Cueto, I., Wang, C. Q. F., Tan, H., Wolk, R. A., Rottinghaus, S. T., Whitley, M. Z., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1318 · Cited by 142
A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
Smith, D. E., Helgason, H., Sulem, P., Björnsdóttir, U. S., Lim, A. C., Sveinbjörnsson, G., Hasegawa, H., Brown, M. E., Ketchem, R. R., Gavala, M. L., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006659 · Cited by 141
Kim, H., Brooks, K. M., Tang, C. C., Wakim, P., Blake, M., Brooks, S. R., Sanchez, G. A. M., de Jesus, A. A., Huang, Y., Tsai, W. L., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.936 · Cited by 139
Recent advances in understanding psoriasis
Eberle, F. C., Brück, J., Holstein, J., Hirahara, K., & Ghoreschi, K. (2016) · F1000Research · doi:10.12688/f1000research.7927.1 · Cited by 138
Self-citationVerden, A., Dimbil, M., Kyle, R. F., Overstreet, B. M., & Hoffman, K. B. (2017) · Drug Safety · doi:10.1007/s40264-017-0622-2 · Cited by 138
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Szilveszter, K. P., Németh, T., & Mócsai, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01862 · Cited by 136
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
Tofacitinib for the treatment of lichen planopilaris: A case series
Yang, C. C., Khanna, T., Sallee, B. N., Christiano, A. M., & Bordone, L. A. (2018) · Dermatologic Therapy · doi:10.1111/dth.12656 · Cited by 134
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
Kurtzman, D. J. B., Wright, N. A., Lin, J., Femia, A. N., Merola, J. F., Patel, M., & Vleugels, R. A. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.0866 · Cited by 133
Förster, M., Chaikuad, A., Bauer, S. M., Holstein, J., Robers, M. B., Corona, C. R., Gehringer, M., Pfaffenrot, E., Ghoreschi, K., Knapp, S., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.008 · Cited by 133
Self-citationType I interferon‐associated cytotoxic inflammation in lichen planus
Wenzel, J., Scheler, M., Proelss, J., Bieber, T. R. M., & Tüting, T. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00527.x · Cited by 132
Brüggen, M., Klein, I., Greinix, H., Bauer, W. M., Kuzmina, Z. J., Rabitsch, W., Kalhs, P., Petzelbauer, P., Knobler, R., Stingl, G., et al. (2013) · Blood · doi:10.1182/blood-2013-07-514372 · Cited by 128
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Self-citationTherapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
Solimani, F., Pollmann, R., Schmidt, T., Schmidt, A., Zheng, X., Savai, R., Mühlenbein, S., Pickert, J., Eubel, V., Möbs, C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01808 · Cited by 126
Self-citationWinthrop, K. L., Wouters, A., Choy, E., Soma, K., Hodge, J. A., Nduaka, C. I., Biswas, P., Needle, E., Passador, S., Mojcik, C. F., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40187 · Cited by 123
Colombel, J. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy150 · Cited by 119
Sands, B. E., Taub, P. R., Armuzzi, A., Friedman, G. S., Moscariello, M., Lawendy, N., Pedersen, R. D., Chan, G. L., Nduaka, C. I., Quirk, D. M., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.059 · Cited by 118
Papp, K. A., Pariser, D. M., Catlin, M., Wierz, G., Ball, G., Akinlade, B., Zeiher, B. G., & Krueger, J. G. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13745 · Cited by 117
Carniti, C., Gimondi, S., Vendramin, A., Recordati, C., Confalonieri, D., Bermema, A., Corradini, P., & Mariotti, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2758 · Cited by 116
The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders
Saluja, R., Ketelaar, M. E., Hawro, T., Church, M. K., Maurer, M., & Nawijn, M. C. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.018 · Cited by 113
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Activation of the JAK/STAT pathway in Behcet’s disease
Virlan, A. T., Dozmorov, M. G., Özdemir, F. T., Yilmaz, V., Ekşioğlu, E., Alıbaz-Öner, F., Özen, G., Wren, J. D., Saruhan‐Direskeneli, G., Sawalha, A. H., et al. (2014) · Genes and Immunity · doi:10.1038/gene.2014.64 · Cited by 110
Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of Vitiligo
Agarwal, P., Rashighi, M., Essien, K. I., Richmond, J. M., Randall, L. M., Pazoki–Toroudi, H., Hunter, C. A., & Harris, J. E. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.529 · Cited by 110
Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo
Ishizaki, M., Akimoto, T., Muromoto, R., Yokoyama, M., Ohshiro, Y., Sekine, Y., Maeda, H., Shimoda, K., Oritani, K., & Matsuda, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003244 · Cited by 108
Wendel, S., Venhoff, N., Frye, B. C., May, A. M., Agarwal, P., Rizzi, M., Voll, R. E., & Thiel, J. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.003 · Cited by 108
Worm, M., Bauer, A., Elsner, P. U., Mahler, V., Molin, S., & Nielsen, T. S. S. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18469 · Cited by 108
Hymes, S. R., Alousi, A. M., & Cowen, E. W. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.11.960 · Cited by 107
Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus
Piccinni, M., Lombardelli, L., Logiodice, F., Tesi, D., Kullolli, O., Biagiotti, R., Giudizi, M. G., Romagnani, S., Maggi, E., & Ficarra, G. (2013) · Oral Diseases · doi:10.1111/odi.12094 · Cited by 103
Works, M. G., Yin, F., Yin, C., Yiu, Y. Y., Shew, K., Tran, T.-T., Dunlap, N., Lam, J. S., Mitchell, T. J., Reader, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400205 · Cited by 102
Fukuyama, T., Ehling, S., Cook, E. H., & Bäumer, W. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.223784 · Cited by 101
Papp, K. A., Bissonnette, R., Gooderham, M., Feldman, S. R., Iversen, L., Soung, J., Draelos, Z. D., Mamolo, C. M., Purohit, V. S., Wang, C., et al. (2016) · BMC Dermatology · doi:10.1186/s12895-016-0051-4 · Cited by 101
Ma, C., Lee, J. K., Mitra, A. R., Teriaky, A., Choudhary, D., Nguyen, T. M., Casteele, N. V., Khanna, R., Panaccione, R., Feagan, B. G., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15297 · Cited by 101
Merola, J. F., Elewski, B. E., Tatulych, S., Lan, S.-P., Tallman, A. M., & Kaur, M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.053 · Cited by 99
Karonitsch, T., Feierl, E., Steiner, C.-W., von Dalwigk, K., Korb, A., Binder, N. B., Rapp, A., Steiner, G. E., Scheinecker, C., Smolen, J. S., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24449 · Cited by 98
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Al-Mutairi, N., Nour, T. M., & Hussain, N. H. (2018) · Dermatology · doi:10.1159/000494613 · Cited by 97
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Liew, S. H. M., Nichols, K. K., Klamerus, K. J., Li, J. Z., Zhang, M., & Foulks, G. N. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.01.028 · Cited by 94
Zhang, J., Tsai, T., Lee, M., Zheng, M., Wang, G., Jin, H., Gu, J., Li, R.-Y., Liu, Q., Jin, C., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.05.004 · Cited by 90
Topical Janus kinase inhibitors: A review of applications in dermatology
Hosking, A., Juhász, M. L. W., & Mesinkovska, N. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.018 · Cited by 89
Curtis, J. R., Xie, F., Yang, S., Bernatsky, S., Chen, L., Yun, H., & Winthrop, K. L. (2018) · Arthritis Care & Research · doi:10.1002/acr.23769 · Cited by 87
Ludbrook, V. J., Hicks, K. J., Hanrott, K., Patel, J., Binks, M. H., Wyres, M. R., Watson, J., Wilson, P., Simeoni, M., Schifano, L. A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14399 · Cited by 86
Targeted Therapies for Autoimmune Bullous Diseases: Current Status
Amber, K. T., Maglie, R., Solimani, F., Eming, R., & Hertl, M. (2018) · Drugs · doi:10.1007/s40265-018-0976-5 · Cited by 85
Self-citationSchmidt, T., Solimani, F., Pollmann, R., Stein, R., Schmidt, A., Stulberg, I., Kühn, K., Eming, R., Eubel, V., Kind, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.044 · Cited by 85
Self-citationBissonnette, R., Luchi, M., Fidelus-Gort, R., Jackson, S., Zhang, H., Flores, R., Newton, R. C., Scherle, P., Yeleswaram, S., Chen, X., et al. (2016) · Journal of Dermatological Treatment · doi:10.3109/09546634.2015.1115819 · Cited by 84
Ding, C., Chen, X., Dascani, P. L., Hu, X., Bolli, R., Zhang, H., McLeish, K. R., & Yan, J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502043 · Cited by 83
Zhou, T., Casanova, N. G., Pouladi, N., Wang, T., Lussier, Y. A., Knox, K. S., & Garcia, J. G. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-04109-6 · Cited by 82
JAK inhibitors and alopecia areata
Gilhar, A., Keren, A., & Paus, R. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32987-8 · Cited by 81
Kim, S. R., Charos, A. E., Damsky, W., HEALD, P. W., Girardi, M., & King, B. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.12.003 · Cited by 80
Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice
Dong, J., Wang, Q.-X., Zhou, C.-Y., Ma, X.-F., & Zhang, Y.-C. (2007) · Lupus · doi:10.1177/0961203306075383 · Cited by 77
Okiyama, N., Furumoto, Y., Villarroel, V. A., Linton, J. T., Tsai, W. L., Gutermuth, J., Ghoreschi, K., Gadina, M., O’Shea, J. J., & Katz, S. I. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.476 · Cited by 73
Self-citationLu, L. D., Stump, K. L., Wallace, N. H., Dobrzański, P., Serdikoff, C., Gingrich, D. E., Dugan, B. J., Angeles, T. S., Albom, M. S., Mason, J. L., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101228 · Cited by 73
Penetration von Mikropartikeln in die menschliche Haut
Lademann, J. M., Schaefer, H. E., Otberg, N., Teichmann, A., Blume‐Peytavi, U., & Sterry, W. (2004) · Der Hautarzt · doi:10.1007/s00105-004-0841-1 · Cited by 70
Cutaneous immunology: basics and new concepts
Yazdi, A. S., Röcken, M., & Ghoreschi, K. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0545-x · Cited by 69
Self-citationWolk, R. A., Armstrong, E. J., Hansen, P. R., THIERS, B. H., Lan, S.-P., Tallman, A. M., Kaur, M., & Tatulych, S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.012 · Cited by 69
Kahl, L. P., Patel, J., Layton, M., Binks, M. H., Hicks, K. J., Léon, G., HACHULLA, E., Machado, D., Staumont-Sallé, D., Dickson, M. A., et al. (2016) · Lupus · doi:10.1177/0961203316640910 · Cited by 66
Kuhn, A., Wenzel, J., & Bijl, M. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0550-0 · Cited by 65
Open‐label pilot study of tofacitinib 2% for the treatment of refractory vitiligo
Mobasher, P., Guerra, R., Li, S. J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18606 · Cited by 65
Vavricka, S. R., Galván, J. A., Dawson, H., Soltermann, A., Biedermann, L., Scharl, M. M., Schoepfer, A. M., Rogler, G., Vavricka, M. P., Terracciano, L., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx158 · Cited by 64
Förster, M., Chaikuad, A., Dimitrov, T., Döring, E., Holstein, J., Berger, B., Gehringer, M., Ghoreschi, K., Müller, S., Knapp, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00571 · Cited by 64
Self-citationTarp, S., Furst, D. E., Boers, M., Luta, G., Bliddal, H., Tarp, U., Asmussen, K. H., Brock, B., Døssing, A., Jørgensen, T. S., et al. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew442 · Cited by 63
Pérez-Baos, S., Barrasa, J. I., Gratal, P., Larranaga‐Vera, A., Prieto‐Potín, I., Herrero‐Beaumont, G., & Largo, R. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13932 · Cited by 62
A perspective on B-cell-targeting therapy for SLE
Looney, R. J., Anolik, J. H., & Sanz, I. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0213-x · Cited by 61
Yang, Q., Zhao, Y., Li, C., Luo, Y., Hao, W., & Zhang, W. (2018) · Medicine · doi:10.1097/md.0000000000011149 · Cited by 60
The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature
Relke, N., & Gooderham, M. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419833609 · Cited by 60
Wei, J. J., Kallenbach, L. R., Kreider, M. E., Leung, T., & Rosenbach, M. A. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.02.006 · Cited by 59
Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis
Juczyńska, K., Woźniacka, A. J., Waszczykowska, E., Danilewicz, M., Wągrowska‐Danilewicz, M., Wieczfińska, J., Pawliczak, R., & Żebrowska, A. (2017) · Mediators of Inflammation · doi:10.1155/2017/6716419 · Cited by 56
von Bubnoff, N. C. C., Ihorst, G., Grishina, O., Röthling, N., Bertz, H., Duyster, J., Finke, J., & Zeiser, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-5045-7 · Cited by 56
Kamijo, H., Miyagaki, T., Hayashi, Y., Akatsuka, T., Otobe, S., Oka, T., Shishido-Takahashi, N., Suga, H., Sugaya, M., & Sato, S. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.713 · Cited by 56
Bechara, R., Antonios, D., Azouri, H., & Pallardy, M. J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.025 · Cited by 55
Harigai, M., Takeuchi, T., Smolen, J. S., Winthrop, K. L., Nishikawa, A., Rooney, T. P., Saifan, C., Issa, M., Isaka, Y., Akashi, N., et al. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1583711 · Cited by 55
Puccetti, A., Fiore, P. F., Pelosi, A., Tinazzi, E., Patuzzo, G., Argentino, G., Moretta, F., Lunardi, C., & Dolcino, M. (2018) · Journal of Immunology Research · doi:10.1155/2018/4246965 · Cited by 54
STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus
Xu, Z., Duan, B., Croker, B. P., & Morel, L. M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.03.009 · Cited by 52
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
Rachubinski, A. L., Estrada, B. E., Norris, D., Dunnick, C. A., Boldrick, J. C., & Espinosa, J. M. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.02.007 · Cited by 51
Gao, L., Bin, L., Rafaels, N. M., Huang, L., Potee, J., Ruczinski, I., Beaty, T. H., Paller, A. S., Schneider, L. C., Gallo, R. L., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.047 · Cited by 50
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
Onda, M., Ghoreschi, K., Steward-Tharp, S. M., Thomas, C. J., O’Shea, J. J., Pastan, I. H., & FitzGerald, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400063 · Cited by 50
Self-citationNakagawa, H., Nemoto, O., Yamada, H., Nagata, T., & Ninomiya, N. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14322 · Cited by 49
Müeller, R. B., Hasler, C. E. J., Popp, F., Mattow, F., Durmisi, M., Souza, A., Hasler, P., Rubbert‐Roth, A., Schulze‐Koops, H., & von Kempis, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101548 · Cited by 49
Are Janus kinase inhibitors superior over classic biologic agents in RA patients?
Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47
Davies, R., Sarkar, I., Hammenfors, D., Bergum, B., Vogelsang, P., Solberg, S. M., Gavasso, S., Brun, J. G., Jonsson, R., & Appel, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00281 · Cited by 45
Chen, Y., Gong, F., Li, Z.-J., Gong, Z., Zhou, Z. C., Ma, S., & Gao, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-07261-1 · Cited by 44
Kubo, S., Nakayamada, S., & Tanaka, Y. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1608821 · Cited by 44
Dorgham, K., Amoura, Z., Parizot, C., Arnaud, L., Francès, C., Pionneau, C., Devilliers, H., Pinto, S., Zoorob, R., Miyara, M., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201445144 · Cited by 42
Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
Nasifoglu, S., Heinrich, B., & Welzel, J. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16468 · Cited by 42
The use of JAK inhibitors in the treatment of progressive systemic sclerosis
Deverapalli, S. C., & Rosmarin, D. M. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14876 · Cited by 40
Cited by
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
New Treatment Addressing the Pathogenesis of Psoriasis
Tokuyama, M., & Mabuchi, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207488 · Cited by 291
Metadata
- Authors
- Solimani, F., Meier, K., & Ghoreschi, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-03
- Volume
- 10
- Pages
- 2847-2847
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2990076552
- Cited by
- 308
- References
- 219
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.